PPAR-α activator pemafibrate lowered plasma insulin-like growth factor-1 level in a patient with acromegaly - PubMed
3 hours ago
- #IGF-1
- #PPAR-α activator
- #acromegaly
- Pemafibrate, a PPAR-α activator, reduced plasma IGF-1 levels in an acromegaly patient.
- The patient was on baseline medication lanreotide (90 mg/month) before pemafibrate treatment.
- A significant decrease in IGF-1 levels was observed and sustained over 12 months of follow-up.
- Pemafibrate also effectively regulated dyslipidemia in the patient.
- In vitro studies suggest potential beneficial effects of pemafibrate in acromegaly treatment.
- Pemafibrate shows promise as a new therapeutic option for acromegaly.